20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency

被引：4
|
作者：
Wasserman, Richard L. [1 ]
Stein, Mark R. [2 ]
Younger, M. Elizabeth M. [2 ]
Fatteh, Shahnaz [3 ]
Haddad, Elie [4 ,5 ]
机构：
[1] Allergy Partners North Texas Res, Dallas, TX USA
[2] Allergy Associates Palm Beaches, North Palm Beach, FL USA
[3] Larkin Community Hosp, South Miami, FL USA
[4] Univ Montreal, CHU St Justine, Dept Pediat, Montreal, PQ, Canada
[5] Univ Montreal, CHU St Justine, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2016年 / 117卷 / 01期
关键词：
REPLACEMENT THERAPY; EFFICACY; SAFETY; IGPRO20; DISEASE;
D O I：
10.1016/j.anai.2016.04.023
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies
    Berger, Melvin
    Rojavin, Mikhail
    Kiessling, Peter
    Zenker, Othmar
    CLINICAL IMMUNOLOGY, 2011, 139 (02) : 133 - 141
  • [42] Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig(R) [octanorm])
    Kobayashi, Roger H.
    Mandujano, Jose Fernando
    Rehman, Syed M.
    Kobayashi, Ai Lan
    Geng, Bob
    Atkinson, Thomas Prescott
    Melamed, Isaac
    Turpel-Kantor, Eva
    Clodi, Elisabeth
    Gupta, Sudhir
    IMMUNOTHERAPY, 2021, 13 (10) : 813 - 824
  • [43] Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review
    Walter, Graham
    Kalicinsky, Chrystyna
    Warrington, Richard
    Miguel, Marianne
    Reyes, Jeannette
    Rubin, Tamar S.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2020, 16 (01):
  • [44] Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder
    Sari, G.
    Bilgin, B. Guven
    Yilmaz, E.
    Aytac, G.
    Karaca, N. Edeer
    Aksu, G.
    Kutukculer, N.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 53 (04) : 177 - 184
  • [45] Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency
    Haddad, Elie
    Berger, Melvin
    Wang, Edward C. Y.
    Jones, Christopher A.
    Bexon, Martin
    Baggish, Jeffrey S.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 281 - 289
  • [46] Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a Practical approach
    Jolles, S.
    Sleasman, J. W.
    ADVANCES IN THERAPY, 2011, 28 (07) : 521 - 533
  • [47] Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
    Keith, Paul K.
    Cowan, Juthaporn
    Kanani, Amin
    Kim, Harold
    Lacuesta, Gina
    Lee, Jason K.
    Chen, Jie
    Park, Michelle
    Gladiator, Andre
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2022, 18 (01):
  • [48] Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies
    Li, Zhaoyang
    Mahmood, Iftekhar
    IMMUNOTHERAPY, 2024, 16 (13) : 895 - 905
  • [49] A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency
    Wasserman, Richard L.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (03) : 325 - 337
  • [50] Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases
    Ochs, Hans D.
    Melamed, Isaac
    Borte, Michael
    Moy, James N.
    Pyringer, Barbara
    Kobayashi, Ai Lan D.
    Knutsen, Alan P.
    Smits, William
    Pituch-Noworolska, Anna
    Kobayashi, Roger H.
    IMMUNOTHERAPY, 2018, 10 (14) : 1193 - 1202
12345